Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations
- PMID: 16456490
Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations
Abstract
The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerability make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.
Similar articles
-
Severe hyponatremia due to desmopressin.J Emerg Med. 2006 Jan;30(1):45-7. doi: 10.1016/j.jemermed.2005.02.020. J Emerg Med. 2006. PMID: 16434334
-
Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.Endocr J. 2015;62(2):195-200. doi: 10.1507/endocrj.EJ14-0368. Epub 2014 Nov 7. Endocr J. 2015. PMID: 25382102
-
Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.Endocr J. 2013;60(9):1085-94. doi: 10.1507/endocrj.ej13-0165. Epub 2013 Jun 28. Endocr J. 2013. PMID: 23811987 Clinical Trial.
-
Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature.Hormones (Athens). 2013 Jan-Mar;12(1):135-41. doi: 10.1007/BF03401295. Hormones (Athens). 2013. PMID: 23624139 Review.
-
Diabetes insipidus: clinical and basic aspects.Pediatr Endocrinol Rev. 2006 Dec;4 Suppl 1:60-5. Pediatr Endocrinol Rev. 2006. PMID: 17261971 Review.
Cited by
-
Desmopressin : safety considerations in patients with chronic renal disease.Drug Saf. 2006;29(7):553-6. doi: 10.2165/00002018-200629070-00001. Drug Saf. 2006. PMID: 16808548 No abstract available.
-
Predicting the Need for Desmopressin Treatment During Inpatient and After Discharge Following Endoscopic Sellar Surgery.Front Neurol. 2022 Feb 17;13:843646. doi: 10.3389/fneur.2022.843646. eCollection 2022. Front Neurol. 2022. PMID: 35250842 Free PMC article.
-
3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus.MAGMA. 2014 Feb;27(1):47-52. doi: 10.1007/s10334-013-0377-4. Epub 2013 Apr 6. MAGMA. 2014. PMID: 23563855
-
Prolonged urinary leakage in the postoperative period of renal hydatic cyst treatment with oral desmopressin: a case report.J Med Case Rep. 2012 Oct 5;6:339. doi: 10.1186/1752-1947-6-339. J Med Case Rep. 2012. PMID: 23039035 Free PMC article.
-
A rare case of pituitrin-induced delayed encephalopathy.Pak J Med Sci. 2014 Sep;30(5):1141-2. doi: 10.12669/pjms.305.5491. Pak J Med Sci. 2014. PMID: 25225543 Free PMC article.